The tweet said, “Drug corporations’ greed is unbelievable. Ariad has raised the price of a leukemia drug to almost $199,000 a year,” and linked to a STAT article about the company’s price hikes. The tweet was not signed with a “-B,” indicating a staff member — not Sen. Sanders — wrote the post, according to the report.
Ariad raised the wholesale acquisition price of its leukemia drug Iclusig four times this year, according to STAT. The treatment costs more than $16,000 for a 30-day pack of pills, which amounts to $199,000 a year.
Cambridge, Mass.-based Ariad’s shares dropped 15 percent on Friday afternoon in response to the tweet, costing investors $387 million, according to the report.
More articles on supply chain:
Drug industry reaps new profits from opioid abuse crisis
3 takeaways from last week’s American Medical Device Summit
Trucking industry provides less financial support to Donald Trump than past Republican nominees: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
